BIOtech Now
Andrew Segerman
In 1992, with the support of the biopharmaceutical industry, Congress created the 340B Drug Discount Program to help uninsured and vulnerable patients gain access to affordable prescription drugs. Over the years, however, there have been growing signs that this program has expanded well past the intent of Congress and that patients may not be seeing the benefits they deserve.
Just last month, the House Energy and Commerce Committee published a review of 340B concluding that the program has grown far beyond its original scope, leading to growing problems with accountability and transparency. And building on these findings, a new study in the New England Journal of Medicine offered fresh evidence that 340B functions almost entirely as a source of revenue for hospitals, rather than as a benefit for vulnerable patients.
In our latest infographic, we dive into the current state of 340B, highlight areas that are in need of reform, and showcase expert viewpoints on the issue.
To view the full infographic, click here.
Powered by WPeMatico